Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phase IV Commitments Are Increasingly Delayed, FDA Report Finds

Executive Summary

The rate of delayed postmarketing commitments has increased since 2005, according to data provided in FDA's annual "Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Commitment Studies.
Advertisement

Related Content

Phase IV Commitments Increasingly Delayed in 2007, FDA Report Finds
Phase IV Commitments Increasingly Delayed in 2007, FDA Report Finds
New Risk Management Landscape For Drugs Offers Fertile Ground For CROs
New Risk Management Landscape For Drugs Offers Fertile Ground For CROs
Post-Marketing Study Deadlines Urged As House Tackles FDA Safety Effort
Post-Marketing Study Deadlines Urged As House Tackles FDA Safety Effort
Senior FDA Staff Has Final Say Over Disputes In Enzi/Kennedy Drug Safety Bill
Senior FDA Staff Has Final Say Over Disputes In Enzi/Kennedy Drug Safety Bill
Advertisement
UsernamePublicRestriction

Register

PS048025

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel